All companies
Visit website
GoSun
OperatingGoSun Inc.
Biotech · Founded 2016
Use More Sun
Post-money valuation ⓘ
$42.4M
As of Feb 2026 · from Reg CF Offering (2025) · pre-money + amount raised, not a traded price
Total raised
$5,073,872
Across 5 rounds since 2017
Latest share price
$3.00
Reg CF Offering (2025) offering price
Financials
FY2015–FY2025 · from SEC filings · hover any figure for its source$1.6M
−$410K
2018
$1.9M
−$252K
2019
$3.9M
$3K
2020
$5.9M
−$31K
2021
$5.7M
−$562K
2022
$2.8M
−$1.4M
2023
$2.6M
−$1.2M
2024
$988K
−$1.1M
2025
RevenueNet income — beside revenue when positive, below the line when a loss
Chart shows the most recent 8 fiscal years; 3 earlier years are in the table below.
Metric
FY2015
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Income statement
Revenue
$671,614
$1,119,257
$1,359,436
$1,564,816
$1,869,934
$3,925,165
$5,872,726
$5,730,329
$2,818,617
$2,600,039
$987,762
Cost of goods sold
$250,722
$470,145
$774,719
$859,013
$1,020,785
-$1,973,993
-$3,381,827
$1,807,067
$1,791,343
$1,403,739
$793,204
Gross margin
63%
58%
43%
45%
45%
50%
42%
68%
36%
46%
20%
Net income
-$21,441
$48,165
$129,074
-$409,507
-$251,950
$2,783
-$31,000
-$562,476
-$1,364,391
-$1,220,051
-$1,124,120
Taxes paid
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Balance sheet
Cash
$566,683
$201,582
$1,077,685
$526,140
$699,115
$1,233,581
$1,490,581
$1,555,801
$1,086,362
$456,536
$1,003,565
Accounts receivable
$0
$27,785
$37,483
$32,404
$108,079
$110,832
$118,828
$3,643
$0
$0
$0
Total assets
$684,579
$620,604
$1,500,766
$1,072,581
$1,425,124
$2,485,882
$3,961,758
$3,890,076
$3,287,198
$2,169,140
$2,423,162
Short-term debt
$674,366
$635,143
$593,770
$104,586
$94,777
$84,302
$134,507
$0
$339,938
$347,801
$1,089,148
Long-term debt
$0
$0
$557,530
$563,115
$485,142
$449,289
$0
$0
$106,583
$0
$0
Total liabilities
$674,366
$635,143
$1,151,300
$667,701
$579,919
$533,591
$134,507
$0
$446,521
$347,801
$1,089,148
Other
Headcount
—
7
—
9
8
10
10
12
10
8
11
Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Post-money = pre-money + amount raised · caps marked$15.1M
post-money
$62.7M
post-money
$41.1M
post-money
$42.4M
post-money
GoSun Stock 2
Round 3
GoSun Common Stock 4
Reg CF Offering (2025)
A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.
Fundraising history
Raised $1.1M / $1.5MInvestors 507Post-money $42.4M
Raised $246.8K / $5MInvestors 189Post-money $41.1M
Round 3Closed
Reg CF annual-report compliance
Not required3+ reports filed & assets ≤ $10M
Filed 9 of 9 annual reports (FY2017–FY2025)
2,539 investors
holder-count proxy
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
View all 43 filings on EDGARSource: ManualCIK 0001706024Share price $3.00
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.